Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. (2019)
Attributed to:
Renewal of the Network of Hubs for Trials Methodology Research.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s40273-019-00826-0
PubMed Identifier: 31372948
Publication URI: http://europepmc.org/abstract/MED/31372948
Type: Journal Article/Review
Volume: 37
Parent Publication: PharmacoEconomics
Issue: 12
ISSN: 1170-7690